News

Arpida has agreed with the FDA to file the NDA in a rolling process. Using a ‘rolling NDA’ allows modules within the overall package to be filed individually.

The majority of the $20 million investment will occur by the end of 2009. Symmetry will move its existing case facility to a larger, new 50,000 square foot

In this study, the NADiA (Nucleic Acid Detection ImmunoAssay) PSA Assay detected levels and increasing levels of prostate specific antigen (PSA) that were previously undetectable using conventional ultra

This patent contains claims covering CRx-191, the company’s lead topical dermatology product candidate, and other product candidates, and will expire in 2022, unless extended. Alexis Borisy, president and

The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw, Poland and involves compounds that appear to be novel antimicrotubule agents. Donald Picker, COO of

In this trial, two groups of six rhesus macaques each were treated intravaginally with 2ml of HEC-based universal placebo or 6% Ushercell gel (the same clinical formulas used

Full enrollment is expected in the first half of 2008, consistent with previous projections, despite expansion of the study. The study currently enrolling patients at 10 of its

Previously available by prescription, MiraLAX (polyethylene glycol 3350 or PEG 3350) became an over-the-counter (OTC) treatment for occasional constipation in early 2007. Due to FDA policy which does

BDC and Living Cell will collaboratively pursue regulatory approval and then conduct a US clinical trial in type 1 diabetes with DiabeCell, Living Cell’s encapsulated porcine insulin producing